needsize said:
My next cycle is combining, among other things, 2 progesterone based drugs, deca and anadrol? I know anti-e's like arimidex dont stop the sides from those, namely gyno which is the only one I'm worried about. I know bromo is supposed to block progesterone, but i was reading up on it in the CPS and it blocks the production of growth hormone, which I obviously dont want. Are there any other drugs that I can use instead?
Anadrol is not a progesterone based drug. I think it's a DHT based one. Deca-D's progestogenic effects can be controlled with RU486(mifepristone)-not recommended! and stanozolol...try 50mgs eod as this dose shouldn't cause too much joint problems.
Tamoxifen should be the agent of choice for anadrol induced gyno..20-40mgs/day and a light diuretic dose for any unwanted bloat.
It has been suggested that the estrogenic effects of oxymetholone may not be as much mediated by estrogen, as by oxymetholone itself activating the estrogen receptor. Because there is little to no aromatisation off oxymetholone, the possible progestational effect was examined first. Similar to that of nandrolone perhaps. But a study2 testing the progestational effects of oxymetholone and methandrostenolone against those of testosterone as well as nandrolone and its metabolites showed that
the progestagenic activity of oxymetholone wasn't even in the neighbourhood of that of testosterone, let alone nandrolone. Ruling out the possibility of progestagenic activity and aromatisation, that only left oxymetholone engaging in a structure with the estrogen receptor itself. Since it has an A-ring similar to that of estradiol (the prime estrogen) so this would be the most logical explanation. Since progesterone acts as an estrogen agonist, it would require circulating estrogen to negotiate such levels of water build-up as oxymetholone causes, so it seemed like a far-fetched idea to begin with.
Bromocriptine inhibits prolactin, but not progesterone. The growth hormone inhibiting effects are only present in acromegalic patients and actually increases GH in normal users.
The endocrine profile of bromocriptine: its application in endocrine diseases.
Lancranjan I.
Bromocriptine, a potent agonist at Dz receptors, was developed as a therapeutic agent for inhibiting prolactin (PRL) secretion in patients with hyperprolactinemia. Besides, its PRL-suppressive effect and a short-lasting growth hormone (GH)-releasing effect in normal volunteers, bromocriptine has no other endocrine effects in healthy subjects. On the other hand, bromocriptine lowers GH secretion in acromegalic patients and ACTH secretion in some patients with Cushing's disease or Nelson's syndrome. The paper reviews the endocrine actions of bromocriptine in man, in normal and pathological conditions, the bromocriptine's mechanism of action and its clinical applications in endocrinology.
B32....
